Inhibition of phosphodiesterase-4D in adults with fragile X syndrome: a randomized, placebo-controlled, phase 2 clinical trial.

For: All,

Although this study focuses on Fragile X syndrome rather than 16p11.2 directly, it may interest families because it tested a drug (BPN14770) that improved language, cognition, and daily functioning in adults with a related neurodevelopmental condition, suggesting potential relevance to other syndromes with overlapping features like autism and intellectual disability.